Exelixis, Inc. (EXEL) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Alameda, CA, United States. Le PDG actuel est Michael Morrissey.
EXEL a date d'introduction en bourse 2000-04-17, 1,147 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $12.3B.
Exelixis, Inc. is an oncology-focused biotechnology company engaged in the discovery, development, and commercialization of cancer treatments. The company's marketed products include CABOMETYX for advanced renal cell carcinoma, COMETRIQ for medullary thyroid cancer, COTELLIC for advanced melanoma, and MINNEBRO for hypertension in Japan. Exelixis maintains an active pipeline of investigational therapies, including XL092, XB002, and XL102, which target various cancer mechanisms through tyrosine kinase inhibition and other novel pathways. The company leverages strategic collaborations with leading pharmaceutical and biotechnology partners including Ipsen, Takeda, Roche, and Bristol-Myers Squibb to advance its research and development efforts. Headquartered in Alameda, California, Exelixis was founded in 1994 and operates globally in the oncology market.
